Download by
Scanning QR Code
No Stock Yet
No Data
Wall Street Set to Open Higher
09:16 AM EDT, 06/17/2022 (MT Newswires) -- US stocks look set to open Friday trading higher as Federal Reserve Chairman Jerome Powell speaks before the inaugural Conference on the International Roles
US Futures Move Higher Friday
08:16 AM EDT, 06/17/2022 (MT Newswires) -- US stock futures are moving higher during Friday's premarket session ahead of remarks to be given by Federal Reserve Chairman Jerome Powell before the inaugu
Top Premarket Decliners
07:54 AM EDT, 06/17/2022 (MT Newswires) -- Addex Therapeutics (ADXN) shares sank 35% after the company said it has canceled a phase 2b/3 study of dipraglurant due to slow patient recruitment. Foghorn
Do Insiders Own Lots Of Shares In Foghorn Therapeutics Inc. (NASDAQ:FHTX)?
The big shareholder groups in Foghorn Therapeutics Inc. (NASDAQ:FHTX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insi
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory s
Morgan Stanley updates biotechs with negative enterprise values & 2022 catalysts
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 pre
Goldman Sachs Adjusts Foghorn Therapeutics' Price Target to $21 from $30, Keeps Buy Rating
11:22 AM EDT, 05/24/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Foghorn Therapeutics Is Maintained at Buy by Goldman Sachs
Foghorn Therapeutics Is Maintained at Buy by Goldman Sachs
Foghorn Therapeutics Price Target Cut to $21.00/Share From $30.00 by Goldman Sachs
Foghorn Therapeutics Price Target Cut to $21.00/Share From $30.00 by Goldman Sachs
Goldman Sachs Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $21
Goldman Sachs maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $30 to $21.
Loading...
No Stock Yet